Lycurim (R-74) in the therapy of chronic lymphocytic leukaemia

Area of Science:

• Immunology
• Hematology
• Oncology

Background:

• Chronic lymphocytic leukemia (CLL) is a heterogeneous lymphoid malignancy.
• Autoimmune complications, such as hemolytic anemia, can occur in CLL patients.
• Immunomodulatory therapies are explored for managing CLL and its associated conditions.

Purpose of the Study:

• To evaluate the clinical efficacy of Lycurim in treating chronic lymphocytic leukemia (CLL).
• To investigate the immunodepressive effects of Lycurim in CLL patients.
• To assess the impact of Lycurim on immunoglobulin levels and lymphocyte subsets.

Main Methods:

• Clinical assessment of 41 patients with CLL treated with Lycurim.
• Immunological investigations to confirm immunodepressive properties.
• Measurement of serum immunoglobulin (IgG, IgA, IgM) levels.
• Analysis of T-lymphocyte and B-lymphocyte (EAC rosette-forming) counts.

Main Results:

• A positive clinical effect was observed in 34 out of 41 CLL patients.
• Lycurim treatment led to a marked positive effect in CLL cases associated with autoimmune hemolytic anemia.
• Immunological investigations confirmed the immunodepressive property of Lycurim.
• Significant reductions in IgG, IgA, and IgM levels were noted post-treatment.
• A decrease in T-lymphocyte count and a trend towards reduced B-lymphocyte counts were observed.

Conclusions:

• Lycurim shows significant clinical efficacy in a majority of CLL patients.
• The drug is particularly beneficial for CLL patients with concurrent autoimmune hemolytic anemia.
• Lycurim exerts an immunodepressive effect, evidenced by decreased immunoglobulin and lymphocyte levels.